Compare DexCom, Inc. (DXCM) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Norfolk Southern Corporation — how do they compare? DexCom, Inc. trades at $77.79 (market cap $28.06B), while Norfolk Southern Corporation trades at $338.26 (market cap $73.79B). The key difference: Norfolk Southern Corporation is far larger — about 2.6× DexCom, Inc.'s market cap, and Norfolk Southern Corporation pays a 1.64% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | NSC | |
|---|---|---|
Market Cap | $28.06B | $73.79B |
Sector | Health | Technology |
52-Week High | $89.53 | $328.54 |
52-Week Low | $54.84 | $260.32 |
Enterprise Value | $27.03B | $89.55B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Norfolk Southern (NSC) trades at $338.82, up 3.67% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 23, 2026. Fundamentals show robust profitability, including a 21.91% net income margin and 17.6% ROE, though valuation multiples like a P/E of 27.68 are elevated. Key news includes ongoing regulatory review of the proposed merger with Union Pacific.
The outlook is mixed: analyst consensus targets $344.40 with a buy rating, but regulatory uncertainty around the merger and high valuation pose risks. Earnings growth and merger progress are critical for upside, while any regulatory setbacks could pressure the stock. Investors should weigh strong fundamentals against execution and macro risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
